GILEAD SCIENCES, INC. (GILD)
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Drug Manufacturers - General
Gilead Sciences, Inc.
- 1.7%
- 21.3M
- 3.18
Float 1.24B · Polygon free float · Nov 2, 2026
The cost to borrow GILD shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 38.1%
- 425
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 21.3M sh |
| Oct 15, 2026 | 20.3M sh |
| Sep 30, 2026 | 21.8M sh |
| Sep 15, 2026 | 18.3M sh |
| Aug 31, 2026 | 23.0M sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 26, 2026 | 425 sh |
| Oct 16, 2026 | 5.9K sh |
| Oct 9, 2026 | 81.4K sh |
| Oct 8, 2026 | 360 sh |
| Sep 15, 2026 | 2.0K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 16, 2026 | 38.1% |
| Nov 13, 2026 | 39.8% |
| Nov 12, 2026 | 46.2% |
| Nov 11, 2026 | 38.4% |
| Nov 10, 2026 | 53.4% |
130 calendar days requested; 91 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for GILD: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 21,271,970 GILD shares were sold short (1.72% of a 1.24B-share float, 3.18 days to cover).